Quoin Pharmaceuticals Surges After Positive QRX003 Trial Update and New Financing

By: Quiver PriceTracker

Posted: 3 weeks, 2 days ago / Aug. 28, 2026 2:49 p.m. UTC

QNRX

Quoin Pharmaceuticals (QNRX) is up 34.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears to be tied primarily to Quoin’s positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, released on August 28, 2026, which showed the study’s primary endpoint was met with statistical significance. Investor sentiment may also be getting a boost from a same-day private placement that brings in substantial upfront capital and extends the company’s projected funding runway.

Details:

Quoin said four of the first six patients, or 66.7%, achieved at least a 1-grade improvement in Investigator Global Assessment at week 12, with a p-value of 0.0087.

The company also said a key secondary endpoint reached statistical significance, and all three patients with moderate-to-severe baseline itch posted a clinically meaningful improvement after 12 weeks.

No treatment-related serious adverse events were reported in the interim analysis, which may have strengthened confidence in QRX003’s risk-benefit profile.

Separately, Quoin announced a private placement for up to about $50 million, including roughly $30.8 million upfront, with the company stating expected aggregate proceeds could support operations into the second half of 2029 if warrants are exercised.

Sources:

Quoin Pharmaceuticals, SEC, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive QNRX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$QNRX Hedge Fund Activity

We have seen 9 institutional investors add shares of $QNRX stock to their portfolio, and 10 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CENTIVA CAPITAL, LP removed 60,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $290,400
ADAR1 CAPITAL MANAGEMENT, LLC removed 58,230 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $384,318
VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 52,477 shares (-61.8%) from their portfolio in Q2 2026, for an estimated $253,988
MILLENNIUM MANAGEMENT LLC added 36,076 shares (+47.3%) to their portfolio in Q2 2026, for an estimated $174,607
CITADEL ADVISORS LLC removed 32,519 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $157,391
RESOLUTE CAPITAL ASSET PARTNERS LLC removed 30,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $198,000
STONEPINE CAPITAL MANAGEMENT, LLC removed 24,729 shares (-31.6%) from their portfolio in Q1 2026, for an estimated $163,211

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.